Vanguard Value offers an alternative to growth-heavy index funds. It also pays a respectable dividend yield. 10 stocks we ...

Let's consider these excellent candidates: CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals (NASDAQ: VRTX), two innovative drugmakers. Here's why they are both buys heading into 2026.

The following players span a variety of industries, so if you pick up more than one, you may gain in diversification.

For many investors, diversification will make the biggest difference between these two funds. VOOG contains 57 more stocks than VUG, and it's also less concentrated in tech. That can help reduce its ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Saylor and Le note in their letter to MSCI that Strategy "has at times traded at multiples higher" than the value of the ...

Yahoo Finance Markets and Data Editor Jared Blikre joins Asking for a Trend host Josh Lipton to discuss three key takeaways ...

Analysts project the U.S. diabetes market will surge past $75 billion by 2031, driven by advanced cell therapies and continuous glucose monitoring systems transforming patient care [3]. Regenerative ...

Crane Harbor Acquisition ( CRANU) ( CRAN) upsized pricing of its IPO of 30M units at a price of $10.00 per unit. The ...

Making its debut on 07/14/2015, smart beta exchange traded fund ALPS (OUSA) provides investors broad exposure to the Style ...

Making its debut on 10/21/2015, smart beta exchange traded fund State Street SPDR Portfolio S&P 500 High Dividend ETF (SPYD) provides investors broad exposure to the Style Box - Large Cap Value ...

Eli Lilly (LLY) and Corbus Pharmaceuticals (CRBP) shares are higher after the companies announced upbeat trial results ...